Literature DB >> 14632763

Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features.

K Takagi1, Y Kawaguchi, M Hara, T Sugiura, M Harigai, N Kamatani.   

Abstract

Vascular damage in systemic sclerosis (SSc) may be a factor in the abnormal regulation of several vasoactive agents. It has been well confirmed that plasma endothelin-1, as a vasoconstrictive factor, is elevated in patients with SSc. However, it is still controversial whether the levels of serum nitric oxide (NO), a strong vasodilator, are increased or decreased in SSc patients compared to healthy donors. In this study, we measured the levels of serum NO metabolites in SSc patients and determined the contribution of the excessive production of NO synthase (NOS)-2 by skin fibroblasts to NO synthesis. Serum NO levels of 45 patients with SSc were significantly higher than those of 20 healthy volunteers. In addition, some clinical features of SSc (the extent of skin fibrosis, short disease duration, and the complication of active fibrosing alveolitis) were all correlated positively with the levels of NO metabolites in SSc patients. To evaluate the levels of NOS-2 produced by skin fibroblasts, skin fibroblast cultures were established from SSc patients and healthy volunteers. Reverse transcription-polymerase chain reaction indicated that NOS-2 mRNA was spontaneously expressed in cultured fibroblasts derived from SSc patients, but not in those derived from healthy normal controls. Immunohistochemical staining also showed that NOS-2 proteins were detected in SSc fibroblasts but not in normal fibroblasts. The production of NO by cultured fibroblasts was visualized directly by a reagent (DAF-2 DA) used for the fluorescent detection of NO. Cultured SSc fibroblasts were capable of NO synthesis in culture media containing L-arginine, whereas normal fibroblasts (with no expression of NOS-2) did not synthesize detectable NO. These observations indicate that NO production is increased markedly in early-stage diffuse cutaneous SSc patients with active fibrosing alveolitis, and that constitutive NOS-2 expression in SSc fibroblasts may contribute to increased NO production.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14632763      PMCID: PMC1808884          DOI: 10.1111/j.1365-2249.2003.02320.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

Review 1.  Regulation of biosynthesis of nitric oxide.

Authors:  C Nathan; Q W Xie
Journal:  J Biol Chem       Date:  1994-05-13       Impact factor: 5.157

Review 2.  Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control.

Authors:  U Förstermann; I Gath; P Schwarz; E I Closs; H Kleinert
Journal:  Biochem Pharmacol       Date:  1995-10-26       Impact factor: 5.858

3.  Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity.

Authors:  C I Chang; J C Liao; L Kuo
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

4.  Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung disease.

Authors:  Y P Moodley; U G Lalloo
Journal:  Chest       Date:  2001-05       Impact factor: 9.410

5.  Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells.

Authors:  Y Allanore; D Borderie; P Hilliquin; A Hernvann; M Levacher; H Lemaréchal; O G Ekindjian; A Kahan
Journal:  Rheumatology (Oxford)       Date:  2001-10       Impact factor: 7.580

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

7.  Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis.

Authors:  Y Kawaguchi; K Suzuki; M Hara; T Hidaka; T Ishizuka; M Kawagoe; H Nakamura
Journal:  Ann Rheum Dis       Date:  1994-08       Impact factor: 19.103

8.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.

Authors:  R M Palmer; A G Ferrige; S Moncada
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

9.  Nitric oxide induces apoptosis in mouse thymocytes.

Authors:  K Fehsel; K D Kröncke; K L Meyer; H Huber; V Wahn; V Kolb-Bachofen
Journal:  J Immunol       Date:  1995-09-15       Impact factor: 5.422

10.  Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients.

Authors:  H Kaur; B Halliwell
Journal:  FEBS Lett       Date:  1994-08-15       Impact factor: 4.124

View more
  17 in total

1.  Serum and bronchoalveolar lavage fluid nitric oxide levels in diffuse systemic sclerosis.

Authors:  Vedat Inal; Kenan Aksu; Gursel Cok; Ferhan Girgin; Gokhan Keser; Fatma Kutay; Eker Doganavsargil
Journal:  Rheumatol Int       Date:  2008-09-27       Impact factor: 2.631

Review 2.  The association between systemic sclerosis, arginine and asymmetric dimethylarginine.

Authors:  Li Zhang; Ya-Nan Wan; Jiu-Hua Zhao; Yu-Jie Wang; Ying-Xin Wang; Jun-Wei Yan; Xiao-Lei Huang; Jing Wang
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

3.  Is Total Serum Nitrite and Nitrate (NOx) Level in Dengue Patients a Potential Prognostic Marker of Dengue Hemorrhagic Fever?

Authors:  Maheshi Mapalagamage; Shiroma Handunnetti; Gayani Premawansa; Sharmila Thillainathan; Tharanga Fernando; Karunayokiny Kanapathippillai; Rajitha Wickremasinghe; Aruna Dharshan De Silva; Sunil Premawansa
Journal:  Dis Markers       Date:  2018-07-05       Impact factor: 3.434

4.  Exon-1 polymorphism of ctla-4 gene is not associated with systemic sclerosis in Iranian patients.

Authors:  A Rajaee; A Ebrahimi; A Fotouhi Ghiam; T Kalantari; A Ghaderi
Journal:  Rheumatol Int       Date:  2005-09-28       Impact factor: 2.631

5.  L-Arginine in pregnant scleroderma patients.

Authors:  Dilia Giuggioli; Michele Colaci; Marco Sebastiani; Clodoveo Ferri
Journal:  Clin Rheumatol       Date:  2010-03-06       Impact factor: 2.980

6.  RGC32 Promotes Bleomycin-Induced Systemic Sclerosis in a Murine Disease Model by Modulating Classically Activated Macrophage Function.

Authors:  Chenming Sun; Shi-You Chen
Journal:  J Immunol       Date:  2018-03-05       Impact factor: 5.422

7.  Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis.

Authors:  Mo Yin Mok; Peter Chin Wah Fung; Clara Ooi; Hung Fat Tse; Yik Wong; Yui Ming Lam; Woon Sing Wong; Chak Sing Lau
Journal:  Clin Rheumatol       Date:  2007-08-15       Impact factor: 2.980

8.  Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis.

Authors:  A Servettaz; P Guilpain; C Goulvestre; C Chéreau; C Hercend; C Nicco; L Guillevin; B Weill; L Mouthon; F Batteux
Journal:  Ann Rheum Dis       Date:  2007-03-15       Impact factor: 19.103

Review 9.  Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited.

Authors:  Armando Gabrielli; Silvia Svegliati; Gianluca Moroncini; Giovanni Pomponio; Mariarosaria Santillo; Enrico V Avvedimento
Journal:  Semin Immunopathol       Date:  2008-06-12       Impact factor: 11.759

10.  Vascular changes in bleomycin-induced scleroderma.

Authors:  Toshiyuki Yamamoto; Ichiro Katayama
Journal:  Int J Rheumatol       Date:  2011-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.